App-Quantinova.ai

The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis

SAW Fuqua - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Fulvestrant

High-throughput single-cell linking of antigen specificities with T cell receptor sequences using de novo generated DNA-linked MHC tetramers

Ning Jiang - American Association of Immunologists (AAI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Generation of a therapeutic monoclonal antibody for acute myeloid leukemia by employing the U937 cell line as a surrogate antigen

Bethany Chen - American Association of Immunologists (AAI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Transgenic expression of human IL15 in NOD-scid IL2rgnull (NSG) mice enhances the development and survival of functional human NK cells

Michael A. Brehm - American Association of Immunologists (AAI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials.

Hongchao Pan - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Association between visceral adiposity, BMI, and clinical outcomes in postmenopausal women with operable breast cancer.

Shalini Dalal - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Intracellular intermolecular relationships of LKB1 in breast cancer.

Binafsha Manzoor Syed - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Competing risks of mortality by PAM50 intrinsic subtype: BC tamoxifen-treated cohort.

Judy-Anne W. Chapman - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Tamoxifen

Chromosomal copy number alterations (CNAs) for risk assessment of ductal carcinoma in situ (DCIS).

Anosheh Afghahi - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Clinical outcomes of estrogen receptor (ER)-negative and progesterone receptor (PgR)-positive invasive breast cancer.

Melissa Chan - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Relative bone loss during aromatase inhibitors therapy: The B-ABLE cohort.

Sonia Servitja - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The value of tamoxifen and trastuzumab in breast cancer treatment: A study based on uptake and use in Sweden.

Nils Erik Wilking - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Trastuzumab

Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer.

Esther Park - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Tamoxifen

Dual anti-HER2 therapy (lapatinib and trastuzumab) plus capecitabine is a very effective and well-tolerated regimen (CLT) in metastatic HER2-positive breast cancer patients.

Jose E. Ales-Martnez - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Capecitabine

Clinical validation of the Prosigna breast cancer prognostic gene signature assay on formalin-fixed paraffin embedded breast cancer tumors with comparison to standard molecular markers.

Roy R. L. Bastien - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Neutrophil-guided dosing of anthracycline/cyclophosphamide chemotherapy in breast cancer: A feasibility study.

Johanna Maria van Pelt-Sprangers - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cyclophosphamide

microRNAs and the expression of the progesterone receptor in breast cancer.

Ayelet Shai - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Prognostic potential of thyroid receptor TR2 in breast cancer.

Katarzyna Joanna Jerzak - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Two different doses of fulvestrant (F) as second- or further-line hormone therapy (HT) in elderly patients with metastatic breast cancer (MBC).

Alessandro Comandone - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Anastrozole

Association between the expression of hormone receptors and HER2/Neu in early breast cancer and overweight or obesity.

Eduardo Richardet - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts